We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ALCLS market cap is 186.55M. The company's latest EPS is USD -1.4793 and P/E is -1.76.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 21.46M | 22.99M | 82.46M | 67.58M | 27.67M |
| Operating Income | -105.09M | -123.55M | -85.44M | -130.68M | -110.85M |
| Net Income | -78.69M | -102.09M | -81.07M | -114.2M | -106.14M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 500.84M | 467.47M | 469.47M | 382.08M | 261.22M |
| Total Liabilities | 50.57M | 112M | 160.63M | 145.6M | 135.28M |
| Total Equity | 450.27M | 355.47M | 308.85M | 236.47M | 125.94M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -68.14M | -69.14M | -80.26M | -104.56M | -87.44M |
| Investing | 35.62M | -35.87M | -54.34M | 7.28M | -2.76M |
| Financing | 236.49M | -3.86M | 27.32M | 47.53M | 1.15M |
| Market Cap | 186.55M |
| Price to Earnings Ratio | -1.76 |
| Price to Sales Ratio | 6.74 |
| Price to Cash Ratio | 2.08 |
| Price to Book Ratio | 1.48 |
| Dividend Yield | - |
| Shares Outstanding | 71.75M |
| Average Volume (1 week) | 101.96k |
| Average Volume (1 Month) | 72.43k |
| 52 Week Change | 42.08% |
| 52 Week High | 3.44 |
| 52 Week Low | 0.888 |
| Spread (Intraday) | 0.07 (2.46%) |
| Company Name | Cellectis Nom Eo 05 |
| Address |
8 rue de la croix- jarry paris, paris 75013 |
| Website | https://www.cellectis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
